• Trigeminal Allodynia and the CGRP/SP–Piezo2 Axis

  2026-08-13

  Liao et al. identify a Ca2+-dependent CGRP/SP–Piezo2 feedback loop linking trigeminal root compression, neuroinflammation, and mechanical allodynia. Their rat and in vitro experiments connect ATP, PKC, ERK1/2, and p38 MAPK signaling with mechanosensory sensitization, providing a mechanistic framework for trigeminal neuralgia research.

• Erastin: A Redox-Context Ferroptosis Inducer

  2026-08-13

  Erastin is a ferroptosis inducer that reveals how cystine metabolism, lipid peroxidation, and tumor-cell state interact. This article uses bladder cancer MCT4 research to develop a more rigorous framework for interpreting oxidative stress assays and ferroptosis experiments.

• Chronic Stress, Mitochondria, and Depression-Like Behavior

  2026-08-13

  A February 2025 rat study links chronic unpredictable mild stress (CUMS) with mitochondrial dysfunction and neuroinflammation in the hippocampus and prefrontal cortex. Its intracerebroventricular MnTBAP rescue experiment provides pharmacological evidence that mitochondrial redox imbalance contributes to stress-induced depression-like behavior, while also highlighting the limits of translating an animal model to human disease.

• Recombinant Human Growth Hormone: Assay Workflows

  2026-08-12

  Build reproducible GH dose–response, chondrocyte differentiation, and IGFBP2–THBS1 mechanism studies with a defined recombinant input. This workflow combines a sensitive growth hormone cell proliferation assay with pathway-level validation for more interpretable growth hormone signaling research.

• P. gingivalis, Neutrophils, and COPD Progression

  2026-08-12

  The reference study identifies a mechanistic oral–lung axis in which Porphyromonas gingivalis reaches the lung and amplifies COPD-like pathology by driving epithelial chemokine production and neutrophil-mediated tissue injury. Its value is not only the observed association between periodontitis and pulmonary disease, but the experimentally defined sequence linking bacterial LPS, NF-κB/p38 MAPK signaling, neutrophil recruitment, and release of destructive proteases.

• Artesunate In Vitro Cancer Assay Workflow

  2026-08-11

  Build more informative Artesunate screens by separating growth inhibition from actual cell killing. This workflow combines controlled dosing, orthogonal viability measurements, and mechanism-oriented follow-up for small cell lung carcinoma research and esophageal squamous cell carcinoma models.

• Biomimetic Microparticles Disrupt Tumor pH Homeostasis

  2026-08-10

  The 2026 ACS Nano study introduces tumor cell-derived microparticles that co-deliver syrosingopine and a pH-responsive doxorubicin prodrug to interfere with both intracellular and extracellular tumor acidity. By coupling lactate-export blockade to drug activation and immune remodeling, the platform links metabolic disruption with chemo-immunotherapy rather than treating either pH compartment in isolation.

• Ceftolozane/Tazobactam: Evidence and Mechanism

  2026-08-09

  This review examines how ceftolozane/tazobactam combines an advanced antipseudomonal cephalosporin with a β-lactamase inhibitor to address resistant gram-negative infections. Its central contribution is the integration of target biology, antimicrobial spectrum, pharmacokinetics, pharmacodynamics, clinical evidence, and safety into a framework for interpreting use in complicated intraabdominal and urinary tract infections.

• SGI-1027 and Everolimus Target Lysosomal Death in RCC

  2026-08-08

  A 2024 Advanced Science study identifies the DNMT1 inhibitor SGI-1027 as a methuosis inducer in renal cancer and shows that it cooperates with everolimus. The combination links lysosomal membrane permeability to both apoptosis and GSDME-dependent pyroptosis, suggesting a strategy for improving treatment of advanced or everolimus-resistant renal cell carcinoma.

• Glucagon–GLP-1R Crosstalk in FRET cAMP Assays

  2026-08-07

  Chepurny et al. used high-throughput FRET measurements of cAMP, pharmacological controls, cellular validation, and molecular modeling to show that glucagon can activate the GLP-1 receptor under relevant experimental conditions. The study reveals receptor promiscuity that matters for interpreting incretin pharmacology and for designing dual- and triagonist strategies in metabolic research.

• Heptamethine Cyanine Dye Targets PR and Golgi in HR+ Breast

  2026-08-07

  A novel heptamethine cyanine dye (CA800-PR) enables targeted suppression of progesterone receptor activity and induces Golgi fragmentation in hormone receptor-positive breast cancer. This approach offers a promising non-hormonal therapeutic strategy with potential for organelle-targeted cancer treatment.

• Tubastatin A in Translational Models: Beyond HDAC6 Inhibitio

  2026-08-06

  Discover how Tubastatin A, a potent HDAC6 inhibitor, is advancing translational research with new insights into cell death, myocardial protection, and assay optimization. This article uniquely bridges mechanistic depth with practical protocols for researchers.

• ARCA EGFP mRNA (5-moUTP): Advancing Polyadenylated mRNA Assa

  2026-08-06

  ARCA EGFP mRNA (5-moUTP) empowers researchers with a robust, low-immunogenicity reporter mRNA, ideal for fluorescence-based transfection controls in mammalian cells. Its advanced cap structure and 5-methoxyuridine modification deliver superior stability and translation efficiency, streamlining reliable assay workflows.

• (R)-MG132 as a Precision Control in Proteasome Assays

  2026-08-05

  (R)-MG132, the biologically inactive MG-132 enantiomer, empowers more rigorous validation in ubiquitin-proteasome system research. By serving as a gold-standard negative control, it ensures that observed cellular effects are truly due to proteasome inhibition and not off-target mechanisms.

• CRISPR Activation for Splice Variant Characterization in Dia

  2026-08-05

  Terkelsen et al. (2024) developed a CRISPR activation (CRISPRa) protocol to induce expression of disease genes in easily accessible skin fibroblasts, enabling direct functional analysis of splice-altering variants in their natural genetic context. This approach addresses the challenge of tissue-specific gene expression in rare disease diagnostics and provides a practical assay for evaluating the impact of splicing mutations.

451 records 8/31 page Previous Next First page 上5页 678910 下5页 Last page